This analysis investigates the risk of angioedema in patients with heart failure associated with (1) sacubitril/valsartan (SV) use comparing those with prior angiotensin-converting enzyme inhibitors (ACEI) use and those with prior angiotensin II receptor blockers use (ARBs, excluding SV) use; (2) SV use comparing those with and without prior ACEI use; and (3) SV use comparing those with and without prior ARB use. This analysis follows up and expands upon the work conducted in the earlier Sentinel drug analysis, Angioedema following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis, which assessed different combinations of SV, ACEI and ARB new user cohorts.
The study period includes data from July 15, 2015 up to February 29, 2020. We distributed this request to five Sentinel Data Partners on January 18, 2022.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.